Primary staging and follow-up of high risk melanoma patients with whole- body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients

Cancer

Volumn 82, Issue 9, 1998, Pages 1664-1671

  Rinne, Daniela ^a   Baum, Richard P ^a   Hör, Gustav ^a   Kaufmann, Roland ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Follow up; Malignant melanoma; Neoplasms; Positron emission tomography; Staging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ABDOMINAL CANCER; ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 0032080718     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2     Document Type: Article

References (36)

1. Friedman RJ, Rigel DS, Silverman MK, Kopf AW, Vossaert KA. Malignant melanoma in the 1990s. CA Cancer J Clin 1991;41:201-6.
2. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J Clin 1994;44:7-26.
3. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure: recent developments in epidemiology. Arch Dermatol 1996;132:444-50.
4. Koh HK. Cutaneous melanoma [review article]. New Engl J Med 1991;325:171-82.
5. Johnson N, Mant D, Newton J, Yudkin PL. Role of primary care in the prevention of malignant melanoma. Br J Gen Pract 1994;44:523-6.
6. Schneider JS, Moore DH, Sagebiel RW. Risk factors for melanoma incidence in prospective follow-up. Arch Dermatol 1994;130:1002-7.
7. Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993;3:395-401.
8. Melia J, Cooper EJ, Frost T, Graham-Brown R, Hunter J, Marsden A, et al. Cancer Research Campaign health education programme to promote the early detection of cutaneous malignant melanoma. II. Characteristics and incidence of melanoma. Br J Dermatol 1995;132:414-21.
9. MacLennan R, Green AC, McLeod GRC, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992;84:1427-31.
10. MacKie RM, Hole DJ. Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status. BMJ 1996;312:1125-8.
11. Scotto J, Pitcher H, Lee JAH. Indications of future decreasing trends in skin melanoma mortality among whites in the United States, Int J Cancer 1991;49:490-7.
12. de Rooij MJM, Rampen FH, Schouten LJ, Neumann HAM. Skin cancer screening focusing on melanoma yields more selective attendance. Arch Dermatol 1995;131:422-5.
13. Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ. Cutaneous melanoma in women. I. Exposure to sunlight, ability to tan, and other risk factors related to ultraviolet light. Am J Epidemiol 1995;141:923-33.
14. Stoelben E, Sturm J, Schmoll J, Keilholz U, Saeger HD. Resektion von solitären Lebermetastasen des malignen Melanoms. Chirurg 1995;66:40-3.
15. Horgan K, Hughes LE. Staging of melanoma [review article]. Clin Radiol 1993;48:297-300.
16. Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, et al. Role of computed tomography in the staging of malignant melanoma. J Clin Oncol 1993;11:638-43.
17. Böni R, Huch-Böni R, Steinert H, Dummer R, Burg G, von Schulthess GK. Antimelanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Dermatology 1995;191:119-23.
18. Kagan R, Witt T, Bines S, Mesleh G, Economou S. Gallium-67 scanning for malignant melanoma. Cancer 1988;61:272-4.
19. Divigi CR, Larson SM. Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Semin Nucl Med 1989;19:252-61.
20. Steinert HC, Huch-Böni RA, Buck A, Böni R, Berthold T, Marincek B, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-d-glucose. Radiology 1995;195:705-9.
21. Critters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
22. Böni R, Huch-Böni RA, Steinert H, Burg G, Buck A, Marincek B, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556-62.
23. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography: a comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 1995;131:1394-8.
24. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thor Cardiovasc Surg 1996;111:642-8.
25. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
26. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
27. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastasic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose. Radiology 1996;199:751-6.
28. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with (F-18)-2-deoxy-2-fluoro-d-glucose PET. Radiology 1993;187:743-50.
29. Böni R. Whole-body positron emission tomography: an accurate staging modality for metastatic melanoma. Arch Dermatol 1996;132:833-4.
30. Böni R, Huch-Böni RA, Steinert H, von Schulthess GK, Burg G. Early detection of melanoma metastasis using fludeoxyglucose F 18 positron emission tomography. Arch Dermatol 1996;132:875-6.
31. Fornage BD, Lorigan JG. Sonographic detection and fine-needle aspiration biopsy of nonpalpable recurrent or metastatic melanoma in subcutaneous tissues. J Ultrasound Med 1989;8:421-4.
32. Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, von Schulthess GK. The value of bone scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors: a prospective study. Eur J Nucl Med 1993;20:1063-9.
33. Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, et al. The usefulness of FDG positron emission tomography for the detection of lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741-7.
34. Larcos G, Massey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Comm 1996;17:197-8.
35. Yao WJ, Hoh JA, Glaspy F. Whole-body FDG PET imaging for staging of malignant melanoma: is it cost effective? J Nucl Med 1994;35:8P.
36. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.